Alva Annett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alva Annett has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Claudia L. Kleinman
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
4 shared publications - Nada Jabado
Department of Human Genetics, McGill University, Montreal, Canada
4 shared publications - Augusto Faria Andrade
Department of Human Genetics, McGill University, Montreal, Quebec, Canada
2 shared publications Benjamin Ellezam
Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montreal, Canada
2 shared publicationsBrian Krug
Department of Human Genetics, McGill University, Montreal, Canada
2 shared publicationsDamien Faury
Department of Pediatrics, McGill University and the Research Institute of the McGill University Heath Centre, Montreal, Canada
2 shared publications
Latest Publications
- Open Access
- 10 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
H3K27M cooperates with ASCL1 to maintain progenitor states and drive gliomagenesis
Histone 3 lysine 27-to-methionine substitutions (H3K27M) drive aggressive diffuse midline gliomas by blocking differentiation of radial glial progenitor cells committed to oligodendrogenesis. We establish prolonged differentiation as a powerful tool to uncover regulators of glioma cell states and demonstrate that the pioneer transcription factor (TF) ASCL1 is a key mediator of H3K27M-driven plasticity and tumorigenesis. H3K27M prevents Polycomb silencing of ASCL1 , co-opting this TF to maintain oligodendroglial progenitor states. Consistently, ASCL1 loss drastically impairs tumor formation in vivo. Mechanistically, ASCL1 synergizes with H3K27M to redistribute the chromatin remodeler BRG1 to regulatory elements co-enriched for ASCL1 and SOX motifs, promoting expression of stem and neural progenitor genes at the expense of mesenchymal genes in DMGs. ASCL1 loss acts as a “fire exit”, enabling alternative differentiation despite H3K27M, underscoring the therapeutic potential of targeting stalled differentiation and tumor plasticity in histone-mutant gliomas and cancers with a stem cell hierarchy.
- 10 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessH3K27M cooperates with ASCL1 to maintain progenitor states and drive gliomagenesis
Histone 3 lysine 27-to-methionine substitutions (H3K27M) drive aggressive diffuse midline gliomas by blocking differentiation of radial glial progenitor cells committed to oligodendrogenesis. We establish prolonged differentiation as a powerful tool to uncover regulators of glioma cell states and demonstrate that the pioneer transcription factor (TF) ASCL1 is a key mediator of H3K27M-driven plasticity and tumorigenesis. H3K27M prevents Polycomb silencing of ASCL1 , co-opting this TF to maintain oligodendroglial progenitor states. Consistently, ASCL1 loss drastically impairs tumor formation in vivo. Mechanistically, ASCL1 synergizes with H3K27M to redistribute the chromatin remodeler BRG1 to regulatory elements co-enriched for ASCL1 and SOX motifs, promoting expression of stem and neural progenitor genes at the expense of mesenchymal genes in DMGs. ASCL1 loss acts as a “fire exit”, enabling alternative differentiation despite H3K27M, underscoring the therapeutic potential of targeting stalled differentiation and tumor plasticity in histone-mutant gliomas and cancers with a stem cell hierarchy.
- 15 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (10) , 1794-1806
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma
Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells—including resident microglia and bone marrow-derived macrophages—as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid–myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.
- 15 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (10) , 1794-1806
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma
Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells—including resident microglia and bone marrow-derived macrophages—as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid–myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.
- Open Access
- 22 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Aberrant EZHIP expression drives tumorigenesis in osteosarcoma
Osteosarcomas (OS) are aggressive bone tumors known for their extensive structural variations and rare recurrent oncogenic driver mutations. In this study, we identify ectopic expression of the oncohistone-mimic EZHIP in 20% of patients across two independent OS cohorts. We demonstrate that reduced deposition of the repressive H3K27me3 mark correlates with poor histological response to neoadjuvant therapy, serving as a predictor of patient outcomes. Through gain- and loss-of-function experiments, we provide functional evidence of the oncogenic activity of EZHIP in enhancing the aggressive characteristics of OS both in vitro and in vivo. EZHIP-induced epigenetic reprogramming reactivates developmental pathways and impedes the differentiation of mesenchymal progenitors, pushing them towards smooth muscle lineage commitment at the cost of other fates. Targeting residual H3K27me3 with EZH2 inhibitors may offer therapeutic benefit in EZHIP-expressing OS. Our findings highlight EZHIP expression as a prevalent driver in OS, offering insights into its pathogenic mechanisms and potential therapeutic strategies for this debilitating cancer.
- 22 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessAberrant EZHIP expression drives tumorigenesis in osteosarcoma
Osteosarcomas (OS) are aggressive bone tumors known for their extensive structural variations and rare recurrent oncogenic driver mutations. In this study, we identify ectopic expression of the oncohistone-mimic EZHIP in 20% of patients across two independent OS cohorts. We demonstrate that reduced deposition of the repressive H3K27me3 mark correlates with poor histological response to neoadjuvant therapy, serving as a predictor of patient outcomes. Through gain- and loss-of-function experiments, we provide functional evidence of the oncogenic activity of EZHIP in enhancing the aggressive characteristics of OS both in vitro and in vivo. EZHIP-induced epigenetic reprogramming reactivates developmental pathways and impedes the differentiation of mesenchymal progenitors, pushing them towards smooth muscle lineage commitment at the cost of other fates. Targeting residual H3K27me3 with EZH2 inhibitors may offer therapeutic benefit in EZHIP-expressing OS. Our findings highlight EZHIP expression as a prevalent driver in OS, offering insights into its pathogenic mechanisms and potential therapeutic strategies for this debilitating cancer.
- Open Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Open AccessComplex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.
- Open Access
- 5 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function
Histone H3-mutant gliomas are deadly brain tumors characterized by a dysregulated epigenome and stalled differentiation. In contrast to the extensive datasets available on tumor cells, limited information exists on their tumor microenvironment (TME), particularly the immune infiltrate. Here, we characterize the immune TME of H3.3K27M and G34R/V-mutant gliomas, and multiple H3.3K27M mouse models, using transcriptomic, proteomic and spatial single-cell approaches. Resolution of immune lineages indicates high infiltration of H3-mutant gliomas with diverse myeloid populations, high-level expression of immune checkpoint markers, and scarce lymphoid cells, findings uniformly reproduced in all H3.3K27M mouse models tested. We show these myeloid populations communicate with H3-mutant cells, mediating immunosuppression and sustaining tumor formation and maintenance. Dual inhibition of myeloid cells and immune checkpoint pathways show significant therapeutic benefits in pre-clinical syngeneic mouse models. Our findings provide a valuable characterization of the TME of oncohistone-mutant gliomas, and insight into the means for modulating the myeloid infiltrate for the benefit of patients.
- 5 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessImmune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function
Histone H3-mutant gliomas are deadly brain tumors characterized by a dysregulated epigenome and stalled differentiation. In contrast to the extensive datasets available on tumor cells, limited information exists on their tumor microenvironment (TME), particularly the immune infiltrate. Here, we characterize the immune TME of H3.3K27M and G34R/V-mutant gliomas, and multiple H3.3K27M mouse models, using transcriptomic, proteomic and spatial single-cell approaches. Resolution of immune lineages indicates high infiltration of H3-mutant gliomas with diverse myeloid populations, high-level expression of immune checkpoint markers, and scarce lymphoid cells, findings uniformly reproduced in all H3.3K27M mouse models tested. We show these myeloid populations communicate with H3-mutant cells, mediating immunosuppression and sustaining tumor formation and maintenance. Dual inhibition of myeloid cells and immune checkpoint pathways show significant therapeutic benefits in pre-clinical syngeneic mouse models. Our findings provide a valuable characterization of the TME of oncohistone-mutant gliomas, and insight into the means for modulating the myeloid infiltrate for the benefit of patients.